CN103443122A - 人胰岛素类似物及其酰化衍生物 - Google Patents

人胰岛素类似物及其酰化衍生物 Download PDF

Info

Publication number
CN103443122A
CN103443122A CN2012800117368A CN201280011736A CN103443122A CN 103443122 A CN103443122 A CN 103443122A CN 2012800117368 A CN2012800117368 A CN 2012800117368A CN 201280011736 A CN201280011736 A CN 201280011736A CN 103443122 A CN103443122 A CN 103443122A
Authority
CN
China
Prior art keywords
chains
seq
insulin
human insulin
insulin analogue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN2012800117368A
Other languages
English (en)
Other versions
CN103443122B (zh
Inventor
孙飘扬
张连山
刘佳建
袁纪军
方春钱
孙长安
袁恒立
王亚里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Priority to CN201280011736.8A priority Critical patent/CN103443122B/zh
Priority to CN201510174792.9A priority patent/CN104788556A/zh
Publication of CN103443122A publication Critical patent/CN103443122A/zh
Application granted granted Critical
Publication of CN103443122B publication Critical patent/CN103443122B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

本发明提供一种人胰岛素类似物及其酰化衍生物和生理耐受盐，本发明还提供给了上述胰岛素类似物的制备方法及其作为治疗剂，特别是作为糖尿病治疗剂的用途。

Description

PCT国内申请，说明书已公开。

Claims (1)

  1. PCT国内申请，权利要求书已公开。
CN201280011736.8A 2011-12-15 2012-11-22 人胰岛素类似物及其酰化衍生物 Active CN103443122B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201280011736.8A CN103443122B (zh) 2011-12-15 2012-11-22 人胰岛素类似物及其酰化衍生物
CN201510174792.9A CN104788556A (zh) 2011-12-15 2012-11-22 人胰岛素类似物及其酰化衍生物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201110422095 2011-12-15
CN2011104220952 2011-12-15
CN201110422095.2 2011-12-15
PCT/CN2012/085054 WO2013086927A1 (zh) 2011-12-15 2012-11-22 人胰岛素类似物及其酰化衍生物
CN201280011736.8A CN103443122B (zh) 2011-12-15 2012-11-22 人胰岛素类似物及其酰化衍生物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201510174792.9A Division CN104788556A (zh) 2011-12-15 2012-11-22 人胰岛素类似物及其酰化衍生物

Publications (2)

Publication Number Publication Date
CN103443122A true CN103443122A (zh) 2013-12-11
CN103443122B CN103443122B (zh) 2016-05-11

Family

ID=48611849

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201280011736.8A Active CN103443122B (zh) 2011-12-15 2012-11-22 人胰岛素类似物及其酰化衍生物
CN201510174792.9A Pending CN104788556A (zh) 2011-12-15 2012-11-22 人胰岛素类似物及其酰化衍生物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201510174792.9A Pending CN104788556A (zh) 2011-12-15 2012-11-22 人胰岛素类似物及其酰化衍生物

Country Status (15)

Country Link
US (1) US9458219B2 (zh)
EP (1) EP2784085A4 (zh)
JP (1) JP6153206B2 (zh)
KR (1) KR20140104994A (zh)
CN (2) CN103443122B (zh)
AU (1) AU2012350586B2 (zh)
BR (1) BR112014013483A2 (zh)
CA (1) CA2858253A1 (zh)
HK (1) HK1188795A1 (zh)
IN (1) IN2014MN00933A (zh)
MX (1) MX2014006698A (zh)
RU (1) RU2014127270A (zh)
TW (1) TW201323439A (zh)
WO (1) WO2013086927A1 (zh)
ZA (1) ZA201404417B (zh)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105491227A (zh) * 2015-11-20 2016-04-13 努比亚技术有限公司 一种消息排列方法和终端
CN106496322A (zh) * 2015-09-07 2017-03-15 江苏恒瑞医药股份有限公司 人胰岛素或其类似物的酰化衍生物的制备方法
CN111909255A (zh) * 2019-05-10 2020-11-10 宁波鲲鹏生物科技有限公司 胰岛素衍生物及其制备方法

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018002416A2 (pt) 2015-08-25 2018-09-18 Novo Nordisk As derivados de insulina e seus usos médicos
EP3260548A1 (en) 2016-06-21 2017-12-27 Enzypep B.V. Enzymatic coupling of (oligo)peptides to the b-chain of an insulin receptor ligand
CN114478747A (zh) * 2016-08-02 2022-05-13 江苏恒瑞医药股份有限公司 一种人胰岛素或其类似物的酰化衍生物
US20210040171A1 (en) * 2018-02-01 2021-02-11 Jiangsu Hengrui Medicine Co., Ltd. Pharmaceutical composition comprising acylated derivative of human insulin analog and preparation method thereof
CN111094572B (zh) * 2018-02-09 2023-04-04 江苏恒瑞医药股份有限公司 一种密码子优化的人胰岛素类似物前体基因和信号肽基因
JP2022511567A (ja) 2018-12-11 2022-01-31 サノフイ インスリンコンジュゲート
IL292762A (en) 2019-12-11 2022-07-01 Novo Nordisk As Innovative insulin analogs and their use
US20240025957A1 (en) 2019-12-30 2024-01-25 Gan & Lee Pharmaceuticals Co., Ltd. Insulin Derivative
CN113773398B (zh) * 2020-06-10 2023-05-23 宁波鲲鹏生物科技有限公司 一种德谷胰岛素衍生物及其应用
EP4347632A1 (en) * 2021-05-24 2024-04-10 Sunshine Lake Pharma Co., Ltd. A novel acylated insulin analog
CA3228912A1 (en) 2021-06-25 2022-12-29 Gan & Lee Pharmaceuticals Co., Ltd. Acylated insulin-containing pharmaceutical composition

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN86106574A (zh) * 1985-08-30 1988-08-03 诺沃工业联合股票公司 人工胰岛素类似物
CN1133598A (zh) * 1993-09-17 1996-10-16 诺沃挪第克公司 酰化的胰岛素
CN1829738A (zh) * 2003-08-05 2006-09-06 诺沃挪第克公司 新型胰岛素衍生物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5008241A (en) 1985-03-12 1991-04-16 Novo Nordisk A/S Novel insulin peptides
DK257988D0 (da) 1988-05-11 1988-05-11 Novo Industri As Nye peptider
JPH03506023A (ja) 1988-07-20 1991-12-26 ノボ　ノルデイスク　アクツイエセルスカプ ポリペプチド
HUT56857A (en) 1988-12-23 1991-10-28 Novo Nordisk As Human insulin analogues
CN1195777A (zh) 1997-05-28 1998-10-14 姚维明 电力拖动实验仪
KR20030004317A (ko) * 1999-12-29 2003-01-14 노보 노르디스크 에이/에스 인슐린 선구물질 및 인슐린 선구물질 유사체의 제조 방법
US7060675B2 (en) * 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US6770625B2 (en) * 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
US7193035B2 (en) 2002-10-29 2007-03-20 Sanofi-Aventis Deutschland Gmbh Crystals of insulin analogs and processes for their preparation
CN1780854A (zh) 2003-04-29 2006-05-31 伊莱利利公司 具有延长时间作用的胰岛素类似物
EP1660531A2 (en) * 2003-08-05 2006-05-31 Novo Nordisk A/S Novel insulin derivatives
CN101721712A (zh) * 2008-10-21 2010-06-09 何明磊 一种双链聚乙二醇－胰岛素复合物及其制备方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN86106574A (zh) * 1985-08-30 1988-08-03 诺沃工业联合股票公司 人工胰岛素类似物
CN1133598A (zh) * 1993-09-17 1996-10-16 诺沃挪第克公司 酰化的胰岛素
CN1829738A (zh) * 2003-08-05 2006-09-06 诺沃挪第克公司 新型胰岛素衍生物

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106496322A (zh) * 2015-09-07 2017-03-15 江苏恒瑞医药股份有限公司 人胰岛素或其类似物的酰化衍生物的制备方法
CN105491227A (zh) * 2015-11-20 2016-04-13 努比亚技术有限公司 一种消息排列方法和终端
CN111909255A (zh) * 2019-05-10 2020-11-10 宁波鲲鹏生物科技有限公司 胰岛素衍生物及其制备方法

Also Published As

Publication number Publication date
AU2012350586A1 (en) 2014-07-03
CA2858253A1 (en) 2013-06-20
EP2784085A4 (en) 2015-07-08
CN103443122B (zh) 2016-05-11
JP6153206B2 (ja) 2017-06-28
TW201323439A (zh) 2013-06-16
WO2013086927A1 (zh) 2013-06-20
KR20140104994A (ko) 2014-08-29
US20140329745A1 (en) 2014-11-06
JP2015501819A (ja) 2015-01-19
ZA201404417B (en) 2016-07-27
EP2784085A1 (en) 2014-10-01
CN104788556A (zh) 2015-07-22
MX2014006698A (es) 2014-07-09
AU2012350586B2 (en) 2017-02-02
IN2014MN00933A (zh) 2015-05-01
RU2014127270A (ru) 2016-02-10
BR112014013483A2 (pt) 2019-09-24
US9458219B2 (en) 2016-10-04
HK1188795A1 (zh) 2014-05-16

Similar Documents

Publication Publication Date Title
CN103443122A (zh) 人胰岛素类似物及其酰化衍生物
CN102625811B (zh) Fgf21突变体及其用途
CN104684576B (zh) 聚乙二醇化的oxm变体
CN111253475B (zh) Glp-1激动多肽化合物及其盐与合成方法及用途
CN113493504B (zh) GIP-Exendin-4嵌合肽的分子改构及其二聚体在治疗糖尿病中的应用
CN102532301B (zh) 一类新型的Exendin-4类似物及其制备方法
CN108271356A (zh) 肠降血糖素-胰岛素缀合物
CN111349155B (zh) 一种胰高血糖素类似物及其制备方法和用途
CN103492412A (zh) 分枝型peg修饰的glp-1类似物及其可药用盐
CN108203462A (zh) 一种制备索马鲁肽的方法
CN106661096A (zh) 新的艾塞那肽类似物及其用途
CN108026157A (zh) 新型胰岛素衍生物及其医学用途
CN101240033B (zh) 一种促胰岛素分泌肽与人血清白蛋白的融合蛋白及其制备方法
CN106866788A (zh) 醋酸奥曲肽制备和醋酸奥曲肽注射液药物组合物
CN107880111A (zh) 一种制备利拉鲁肽的方法
CN101627056A (zh) Y型聚乙二醇修饰的g-csf及其制备方法和应用
CN101041693B (zh) 一种降血糖多肽及其应用
CN113429471B (zh) 长效glp-1多肽类似物及其制备方法和应用
CN107847546A (zh) 聚乙二醇化的胃泌酸调节素变体
US4622386A (en) [1,7-di-alanine]calcitonin
JPH05505514A (ja) Ｏ―グリコシル化ｉｇｆ―１
CN106860854A (zh) 醋酸奥曲肽注射液药物组合物和醋酸奥曲肽
EP2915817A1 (en) Method for preparing exenatide
CN106554409A (zh) 一种长效胰高血糖素样肽-1类似物及其应用
CN107529533A (zh) 一类可自组装成水凝胶的pH敏感多肽及其作为装载药物材料的应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1188795

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1188795

Country of ref document: HK